HGHAF yields 340.32% · PFE yields 6.13%● Live data
📍 HGHAF pulled ahead of the other in Year 1
Combined, HGHAF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HGHAF + PFE for your $10,000?
High Arctic Energy Services Inc., an oilfield services company, provides oilfield services to exploration and production companies in Canada and Papua New Guinea. The company operates through three segments: Drilling Services, Production Services, and Ancillary Services. It offers snubbing services, including foothills standalone snubbing system for completions and workovers; hydraulic workover units, such as a patented L-Frame equipment configuration; rig assist snubbing unit, a truck-mounted hydraulic system to manage underbalanced wellbore conditions; and power tower to install a snubbing unit and blowout preventers in one lift. The company also rents oilfield equipment comprising accumulators, blowout preventers, casing cutters and scrappers, hydraulic catwalks, rig shacks, chokes, boilers, boiler blowdown tanks, generators, light towers, cross over and rotary subs, elevators, EUE collars, fire suppression kits, fuel tank skids, hot tap kits, mud cans, pickers, pipe racks, power swivels, pumps, slips, spools, flanges, thread washers, tongs, trailers and accommodations, tubing, gate, plug, hydraulic/air actuated, and safety valves; and kelly cocks for drilling, completions, workover, and abandonment of oil and gas operations. In addition, it provides nitrogen pumping units; and well servicing. Further, the company owns and operates two heli-portable drilling rigs in Papua New Guinea; and offers support equipment, such as rig matting, crawler cranes, water pumps, forklifts/wheel loaders, telehandlers, lighting towers, camps, trucks, wash-down packages, vehicles, and drill pipes and BHA. High Arctic Energy Services Inc. was founded in 1993 and is headquartered in Calgary, Canada.
Full HGHAF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.